叠氮化物与炔烃的铜催化的“点击”反应已成为在药物化学中构建1,4-取代的1 H -1,2,3-三唑的流行方法,并且该方法在实验室规模内得到了应用。新型大环内酯类化合物的制备1。然而,关键叠氮化物组分的制造以及其随后在铜催化剂的存在下的大规模使用与潜在的安全隐患有关。因此,开发了一种序列,其中通过α,α-二氯甲苯磺酰基cyclo与胺的环缩合,完成了1,4-取代的1 H -1,2,3-三唑在1中的构建。
叠氮化物与炔烃的铜催化的“点击”反应已成为在药物化学中构建1,4-取代的1 H -1,2,3-三唑的流行方法,并且该方法在实验室规模内得到了应用。新型大环内酯类化合物的制备1。然而,关键叠氮化物组分的制造以及其随后在铜催化剂的存在下的大规模使用与潜在的安全隐患有关。因此,开发了一种序列,其中通过α,α-二氯甲苯磺酰基cyclo与胺的环缩合,完成了1,4-取代的1 H -1,2,3-三唑在1中的构建。
Triazole compounds and methods of making and using the same
申请人:Bhattacharjee Ashoke
公开号:US20100016956A1
公开(公告)日:2010-01-21
The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. The compounds have the following structure: wherein T is the macrocyclic part.
Triazole Compounds and Methods of Making and Using the Same
申请人:Melinta Therapeutics, Inc.
公开号:US20160031926A1
公开(公告)日:2016-02-04
The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.
Triazole Compounds And Methods Of Making And Using The Same
申请人:Melinta Therapeutics, Inc.
公开号:US20180094016A1
公开(公告)日:2018-04-05
The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.